Csaba M.
- Country
- Hungary
- Department
- Tudogyogyaszati Osztaly
Research Overview
- Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Patients With Previously Treated TROP2-Positive Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Comparison of Sotorasib Plus Combination Therapy Versus Pembrolizumab Plus Combination Therapy in PD-L1 Negative KRAS p.G12C Positive Advanced Non-Squamous NSCLC
- Phase 3 Study of BAY 2927088 vs. Standard of Care in HER2-Mutant Advanced NSCLC
Data & Insights
Has run more than one trial at 122 of 363 partner sites.
Specializations
Lung Cancer Research
The investigator specializes in treating advanced non-small cell lung cancer (NSCLC), with particular expertise in cases involving HER2 mutations and metastatic disease.
- HER2-Mutated NSCLC
- Advanced Stage Lung Cancer
- Metastatic Disease Management
Their research extends to innovative therapeutic approaches for lung cancer treatment.
Targeted Therapies
The investigator focuses on developing and evaluating targeted therapeutic approaches, particularly those directed at human epidermal growth factor receptor 2 (HER2) mutations.
- Novel Drug Development
- Molecular Targeting
- Treatment Resistance
Their work encompasses evaluation of novel therapeutic agents against established standards of care.
Immunotherapy Research
The investigator explores combination therapy approaches including immunotherapy agents and their integration with conventional chemotherapy.
- Immunotherapy Combinations
- PD-L1 Expression Studies
- Treatment Response Assessment
Their research includes evaluation of treatment efficacy in various patient populations.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.